TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Continued Early Intervention for Recent-onset Schizophrenia. A Randomized Controlled Study.
Brief Summary: The purpose of this study was to determine whether outreach integrated treatment of first episode schizophrenia was more effecive than standard outpatient treatment.


Options:
A: Arm Label: Case Management (1 year); Type: EXPERIMENTAL; Interventions: Behavioral: Community Case Management | Arm Label: Standard Care (1 year); Type: NO_INTERVENTION; Interventions: Behavioral: Community Case Management | Intervention Type: BEHAVIORAL; Name: Community Case Management; Assigned to Arm(s): Case Management (1 year), Standard Care (1 year)
B: Intervention Type: BEHAVIORAL; Name: integrated psychosocial treatment (behavior); Assigned to Arm(s): N/A
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive training | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive training | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): 1, 2
D: Intervention Type: BEHAVIORAL; Name: Integrated treatment, family involvement; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Social skills training; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Continued Early Intervention for Recent-onset Schizophrenia. A Randomized Controlled Study.
Brief Summary: The purpose of this study was to determine whether outreach integrated treatment of first episode schizophrenia was more effecive than standard outpatient treatment.


Options:
A: Arm Label: case management (4 yrs); Type: EXPERIMENTAL; Interventions: Behavioral: stage-specific case-management | Arm Label: case management (2 yrs) and standard care (2 yrs); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: stage-specific case-management | Arm Label: standard care (4 yrs); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: stage-specific case-management; Assigned to Arm(s): case management (2 yrs) and standard care (2 yrs), case management (4 yrs)
B: Arm Label: Treatment As Usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment As Usual (TAU) | Arm Label: TAU+CBT for pts+Family Intervention+CM; Type: EXPERIMENTAL; Interventions: Behavioral: TAU+CBT for pts+Family Intervention+CM. | Intervention Type: OTHER; Name: Treatment As Usual (TAU); Assigned to Arm(s): Treatment As Usual (TAU) | Intervention Type: BEHAVIORAL; Name: TAU+CBT for pts+Family Intervention+CM.; Assigned to Arm(s): TAU+CBT for pts+Family Intervention+CM
C: Intervention Type: BEHAVIORAL; Name: integrated psychosocial treatment (behavior); Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Integrated treatment, family involvement; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Social skills training; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Continued Early Intervention for Recent-onset Schizophrenia. A Randomized Controlled Study.
Brief Summary: The purpose of this study was to determine whether outreach integrated treatment of first episode schizophrenia was more effecive than standard outpatient treatment.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: maintained antipsychotic treatment vs. stepwise drug discontinuation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: maintained antipsychotic treatment vs. stepwise drug discontinuation | Intervention Type: OTHER; Name: maintained antipsychotic treatment vs. stepwise drug discontinuation; Assigned to Arm(s): 1, 2
B: Intervention Type: BEHAVIORAL; Name: integrated psychosocial treatment (behavior); Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: dosing; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Haloperidol, Risperidone (drug) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol, Risperidone (drug) | Intervention Type: DRUG; Name: Haloperidol, Risperidone (drug); Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Local Ischemic Preconditioning in Patients With Type 1 Diabetes in Vivo
Brief Summary: In this proof-of-concept study, forearm vulnerability to ischemic exercise is studied in patients with type 1 diabetes mellitus with and without prior ischemic preconditioning (short period of ischemia that protects against subsequent ischemic exercise). Annexin A5 scintigraphy is used to quantify subtle signs of mild and reversible forearm injury that results from ischemic exercise.

The following hypotheses are tested:

1. Patients with type 1 diabetes are not more vulnerable to ischemic injury as compared with previously studied healthy volunteers.
2. Ischemic preconidtioning is still present in patients with type 1 diabetes. Depending on the validity of hypothesis 2, the effect of short pharmacological interventions are studied on vulnerability to forearm ischemia/reperfusion injury in the absence or presence of local forearm ischemic preconditioning.


Options:
A: Arm Label: RIPCcom group; Type: EXPERIMENTAL; Interventions: Procedure: remote ischemic pre and postconditioning (RIPC) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: remote ischemic pre and postconditioning (RIPC); Assigned to Arm(s): RIPCcom group
B: Arm Label: ExerciseTr; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: Remote ischemic preconditioning group; Type: EXPERIMENTAL; Interventions: Procedure: remote ischemic preconditioning | Arm Label: Control patient group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): ExerciseTr | Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): Remote ischemic preconditioning group
C: Intervention Type: PROCEDURE; Name: Ischemic preconditioning; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Forearm ischemic exercise; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Annexin A5 scintigraphy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Diazoxide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glibenclamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: adenosine; Assigned to Arm(s): N/A
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: donor; Type: EXPERIMENTAL; Interventions: Device: remote ischaemic preconditioning | Arm Label: recipient; Type: EXPERIMENTAL; Interventions: Device: remote ischaemic preconditioning | Intervention Type: DEVICE; Name: remote ischaemic preconditioning; Assigned to Arm(s): donor, recipient

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP)
Brief Summary: This is a study in diabetic patients with at least one additional cardiovascular risk factor and normoalbuminuria prior to randomization.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Tablets | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Tablets; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP)
Brief Summary: This is a study in diabetic patients with at least one additional cardiovascular risk factor and normoalbuminuria prior to randomization.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2
B: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
C: Arm Label: A-1, B-1; Type: ACTIVE_COMPARATOR; Interventions: Drug: trandolapril | Arm Label: A-2, B-2; Type: ACTIVE_COMPARATOR; Interventions: Drug: trandolapril/verapamil | Arm Label: A-3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: A-4; Type: ACTIVE_COMPARATOR; Interventions: Drug: verapamil | Intervention Type: DRUG; Name: trandolapril; Assigned to Arm(s): A-1, B-1 | Intervention Type: DRUG; Name: trandolapril/verapamil; Assigned to Arm(s): A-2, B-2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A-3 | Intervention Type: DRUG; Name: verapamil; Assigned to Arm(s): A-4
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Tablets | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Tablets; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP)
Brief Summary: This is a study in diabetic patients with at least one additional cardiovascular risk factor and normoalbuminuria prior to randomization.


Options:
A: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
B: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Tablets | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Tablets; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Indapamide SR 1.5mg; Perindopril 2-4mg; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP)
Brief Summary: This is a study in diabetic patients with at least one additional cardiovascular risk factor and normoalbuminuria prior to randomization.


Options:
A: Arm Label: Nurse administered; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse administered | Arm Label: Nurse & BP monitor; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse administered, Device: BP Monitor | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home BP Monitor; Type: EXPERIMENTAL; Interventions: Device: BP Monitor | Intervention Type: BEHAVIORAL; Name: Nurse administered; Assigned to Arm(s): Nurse & BP monitor, Nurse administered | Intervention Type: DEVICE; Name: BP Monitor; Assigned to Arm(s): Home BP Monitor, Nurse & BP monitor
B: Arm Label: Standard Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet, Behavioral: Exercise, Behavioral: Stop smoking, Drug: Glucose lowering therapy, Drug: Blood pressure lowering therapy, Drug: Lipid lowering therapy | Arm Label: Intensive Treatment Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Behavioral: Stop smoking, Drug: Glucose lowering therapy, Drug: Blood pressure lowering therapy, Drug: Lipid lowering therapy | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: BEHAVIORAL; Name: Stop smoking; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Glucose lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Blood pressure lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Lipid lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm
C: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Tablets | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Tablets; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)
Brief Summary: This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil, Drug: Hydrochlorothiazide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atenolol, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atenolol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: atenolol; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)
Brief Summary: This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.


Options:
A: Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil, Drug: Hydrochlorothiazide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atenolol, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atenolol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: atenolol; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: 40mg Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 40mg Enoxaparin | Arm Label: 60mg Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 60mg Enoxaparin | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: DRUG; Name: 40mg Enoxaparin; Assigned to Arm(s): 40mg Enoxaparin | Intervention Type: DRUG; Name: 60mg Enoxaparin; Assigned to Arm(s): 60mg Enoxaparin | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)
Brief Summary: This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil, Drug: Hydrochlorothiazide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atenolol, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atenolol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: atenolol; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atenolol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: reserpine; Assigned to Arm(s): N/A
C: Arm Label: Inhaled heparin; Type: EXPERIMENTAL; Interventions: Drug: Unfractionated heparin | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Inhaled heparin
D: Arm Label: Nafamostat; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat Mesilate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nafamostat Mesilate; Assigned to Arm(s): Nafamostat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single-center, Open-label, Controlled, Randomized Study to Investigate the Impact of a Sequential Oral Contraceptive (SH T00658ID) as Compared to a Sequential Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D00264A) on Plasma Lipids, Hemostatic Variables, and Carbohydrate Metabolism in Healthy Female Volunteers Aged 18-50 Years Over 7 Treatment Cycles, Including the Pharmacokinetics
Brief Summary: The purpose of this study is to confirm the safety of SH T00658ID with regard to plasma lipids, hemostatic variables, and carbohydrate metabolism. In addition, the pharmacokinetic parameter following the long term administration of SH T00658ID will be assessed.


Options:
A: Intervention Type: BEHAVIORAL; Name: Quick start oral contraceptive initiation; Assigned to Arm(s): N/A
B: Arm Label: NOMAC-E2; Type: EXPERIMENTAL; Interventions: Drug: NOMAC-E2 | Arm Label: DRSP-EE; Type: ACTIVE_COMPARATOR; Interventions: Drug: DRSP-EE | Intervention Type: DRUG; Name: NOMAC-E2; Assigned to Arm(s): NOMAC-E2 | Intervention Type: DRUG; Name: DRSP-EE; Assigned to Arm(s): DRSP-EE
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: SH D00264A (Triquilar) | Intervention Type: DRUG; Name: EV/DNG (Qlaira, BAY86-5027, SH T00658K); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SH D00264A (Triquilar); Assigned to Arm(s): Arm 2
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: SH D 593 B (Miranova) | Intervention Type: DRUG; Name: EV/DNG (Qlaira, BAY86-5027, SH T00658K); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SH D 593 B (Miranova); Assigned to Arm(s): Arm 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Double-blind, Double-dummy, Controlled, Randomized Study to Evaluate Cycle Control and Safety of a Four Phasic Oral Contraceptive (SH T00658ID) in Comparison to an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D 593 B) in Healthy Female Volunteers Aged Between 18 and 50 Years.
Brief Summary: The aim of this study is to evaluate bleeding pattern, cycle control, and safety of this new four-phasic oral contraceptive in comparison to a reference OC.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: SH D 593 B (Miranova) | Intervention Type: DRUG; Name: EV/DNG (Qlaira, BAY86-5027, SH T00658K); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SH D 593 B (Miranova); Assigned to Arm(s): Arm 2
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: SH D00264A (Triquilar) | Intervention Type: DRUG; Name: EV/DNG (Qlaira, BAY86-5027, SH T00658K); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SH D00264A (Triquilar); Assigned to Arm(s): Arm 2
C: Intervention Type: BEHAVIORAL; Name: Quick start oral contraceptive initiation; Assigned to Arm(s): N/A
D: Arm Label: NOMAC-E2; Type: EXPERIMENTAL; Interventions: Drug: NOMAC-E2 | Arm Label: DRSP-EE; Type: ACTIVE_COMPARATOR; Interventions: Drug: DRSP-EE | Intervention Type: DRUG; Name: NOMAC-E2; Assigned to Arm(s): NOMAC-E2 | Intervention Type: DRUG; Name: DRSP-EE; Assigned to Arm(s): DRSP-EE

Answer: A